信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

休市中 04-19 16:08:35

33.200

-0.500

-1.48%

最高33.550	最低32.300	成交量569.41万
今开33.550	昨收33.700	日振幅3.71%
总市值538.73亿	流通市值538.73亿	总股本16.23亿
成交额1.88亿	换手率0.35%	流通股本16.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":33.2,"timestamp":1713514115029,"preClose":33.7,"halted":0,"volume":5694087,"delay":0,"floatShares":1622682897,"shares":1622682897,"eps":-0.7117389,"marketStatus":"休市中","marketStatusCode":7,"change":-0.5,"latestTime":"04-19 16:08:35","open":33.55,"high":33.55,"low":32.3,"amount":187885353,"amplitude":0.037092,"askPrice":33.2,"askSize":188500,"bidPrice":33.15,"bidSize":21000,"shortable":3,"etf":0,"ttmEps":-0.7127421097971649,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713749400000},"adr":0,"listingDate":1540915200000,"adjPreClose":33.7,"openAndCloseTimeList":[[1713490200000,1713499200000],[1713502800000,1713513600000]],"volumeRatio":0.9382518443744966,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK"},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"2428679335","title":"降脂药赛道大变局：他汀药物时代正在逝去","url":"https://stock-news.laohu8.com/highlight/detail?id=2428679335","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2428679335?lang=zh_cn&edition=full","pubTime":"2024-04-17 08:52","pubTimestamp":1713315162,"startTime":"0","endTime":"0","summary":"新型降脂药PCSK9抑制剂在安全性和有效性方面均超越了他汀类药物，不仅为患者提供了更多降脂治疗方案，也让高血脂这个逐渐萎缩的赛道重新有了新的增长点。","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/33e888f2-648a-44e6-b4c4-d354df21ccc6.jpeg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/33e888f2-648a-44e6-b4c4-d354df21ccc6.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3712914","is_publish_highlight":false,"gpt_icon":0},{"id":"2427812625","title":"信达生物04月16日主力资金流出173万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2427812625","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427812625?lang=zh_cn&edition=full","pubTime":"2024-04-16 16:15","pubTimestamp":1713255321,"startTime":"0","endTime":"0","summary":"04月16日, 信达生物股价跌3.21%，报收34.70元，成交金额2.03亿元，换手率0.36%，振幅6.00%，量比1.04。信达生物今日主力资金净流出173万元，连续3日净流出，上一交易日主力净流出157万元，今日环比增加10.19%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为72.73%，平均跌幅为1.43%。该股近5个交易日下跌8.41%，主力资金累计净流出1574万元；近20日主力资金累计净流出9939万元，其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161615468b299220&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161615468b299220&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427139158","title":"【券商聚焦】招银国际料今年中国医药行业有望回归健康增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2427139158","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2427139158?lang=zh_cn&edition=full","pubTime":"2024-04-16 14:56","pubTimestamp":1713250565,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际表示，年初至今，MSCI中国医疗指数下跌22.7%，跑输MSCI中国指数23.3%。展望2024年，随着行业监管常态化进行，新冠基数影响逐渐消退，中国医药行业有望回归健康增长。另外，行业监管仍呈现持续高压态势，预计院内刚需将在下半年出现需求复苏。该行认为，行业严格监管或将常态化，然而，诊疗秩序逐步正常，院内产品和服务的需求仍将保持健康。考虑到基数原因，该行预期行业或将于今年下半年加速增长。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/YjQxYWY4NjkyMTU2YjM4ZTVhNGFhMzYzNjE2NzgxMDU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/YjQxYWY4NjkyMTU2YjM4ZTVhNGFhMzYzNjE2NzgxMDU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935150","is_publish_highlight":false,"gpt_icon":0},{"id":"2427859583","title":"信达生物宣布任命Nageatte Ibrahim博士为肿瘤学首席医学官","url":"https://stock-news.laohu8.com/highlight/detail?id=2427859583","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2427859583?lang=zh_cn&edition=full","pubTime":"2024-04-16 08:00","pubTimestamp":1713225600,"startTime":"0","endTime":"0","summary":"Nageatte Ibrahim博士拥有在Merck公司（默沙东）和GSK公司超过11年的肿瘤领域工业界药品开发管理和9年医疗及医学院校工作经验。加入信达生物前，Ibrahim博士在Merck公司担任肿瘤临床开发副总裁。信达生物创始人、董事长兼首席执行官俞德超博士表示：\"热忱欢迎Nageatte Ibrahim博士加入信达生物并担任肿瘤学首席医学官，Ibrahim博士在临床开发肿瘤领域拥有丰富的经验以及卓越的领导能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4387679_ZH87679_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427847047","title":"信达生物制药（苏州）有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2427847047","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2427847047?lang=zh_cn&edition=full","pubTime":"2024-04-15 15:21","pubTimestamp":1713165702,"startTime":"0","endTime":"0","summary":"4月15日，据CDE官网消息，信达生物制药（苏州）有限公司联合申请药品“IBI133”，获得临床试验默示许可，受理号CXSL2400085。公示信息显示，药品“IBI133”适应症：不可切除的局部晚期或转移性实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415152143877e4ae6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415152143877e4ae6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427658092","title":"南向资金4月12日净买入信达生物100.76万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2427658092","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427658092?lang=zh_cn&edition=full","pubTime":"2024-04-15 09:31","pubTimestamp":1713144674,"startTime":"0","endTime":"0","summary":"4月12日, 南向资金增持信达生物100.76万股，连续3日增持。截止当日收盘，港股通共持有信达生物32720.91万股，占流通股20.15%。信达生物近5个交易日上涨4.48%，港股通累计增持73.06万股；近20个交易日下跌7.89%，港股通累计减持223.73万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415094618877cfdcd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240415094618877cfdcd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426249475","title":"信达生物4月11日获南向资金加仓180.66万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426249475","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426249475?lang=zh_cn&edition=full","pubTime":"2024-04-12 09:31","pubTimestamp":1712885470,"startTime":"0","endTime":"0","summary":"4月11日, 南向资金增持信达生物180.66万股。截止当日收盘，港股通共持有信达生物32620.15万股，占流通股20.09%。信达生物近5个交易日上涨3.46%，港股通累计减持188.26万股；近20个交易日下跌6.50%，港股通累计减持415.04万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404120942228b13c97e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404120942228b13c97e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426904936","title":"信达生物4月8日遭南向资金减持257.41万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426904936","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426904936?lang=zh_cn&edition=full","pubTime":"2024-04-09 09:31","pubTimestamp":1712626288,"startTime":"0","endTime":"0","summary":"4月8日，南向资金减持信达生物257.41万股。截止当日收盘，港股通共持有信达生物32390.43万股，占流通股19.95%。港股通减持金额前五个股分别为赛生药业、联想集团、瑞声科技、安踏体育、汇丰控股。信达生物近5个交易日下跌4.94%，港股通累计减持287.71万股；近20个交易日下跌5.68%，港股通累计减持754.05万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090946228756aa1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090946228756aa1b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426623977","title":"信达生物制药（苏州）有限公司药品纳入突破性治疗药物程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2426623977","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426623977?lang=zh_cn&edition=full","pubTime":"2024-04-09 08:04","pubTimestamp":1712621076,"startTime":"0","endTime":"0","summary":"4月9日，据CDE官网消息，信达生物制药(苏州)有限公司、信达生物制药(苏州)有限公司联合申请的药品“IBI310”，经审核，同意纳入突破性治疗药物程序，公示截止日期2024年4月9日。公示详细信息显示，“BDB-001注射液”药品类型为治疗用生物制品，拟定适应症(或功能主治)：本品联合信迪利单抗用于可切除的高微卫星不稳定性(MSI-H)或错配修复基因缺陷型(dMMR)结肠癌的新辅助治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090825558b006e38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404090825558b006e38&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425603401","title":"信达生物在美国癌症研究协会（AACR）2024年会公布多项创新管线的临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2425603401","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2425603401?lang=zh_cn&edition=full","pubTime":"2024-04-08 08:40","pubTimestamp":1712536800,"startTime":"0","endTime":"0","summary":"美国罗克维尔和中国苏州2024年4月8日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司，今日宣布在 2024 年美国癌症研究协会年会上公布多项最新临床前数据，包括公司旗下一系列双抗及抗体偶联药物肿瘤管线。IBI343针对Claudin 18.2阳性HER2阴性胃癌的临床三期试验正在筹备中。ISAC 靶向肿瘤组织并特异性激活肿瘤内天然免疫细胞，激活下游免疫反应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4381495_ZH81495_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2424898579","title":"信达生物04月03日遭主力抛售1079万元 环比增加408.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2424898579","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424898579?lang=zh_cn&edition=full","pubTime":"2024-04-03 16:15","pubTimestamp":1712132150,"startTime":"0","endTime":"0","summary":"04月03日, 信达生物股价跌4.11%，报收36.15元，成交金额2.34亿元，换手率0.40%，振幅3.98%，量比0.86。信达生物今日主力资金净流出1079万元，连续3日净流出，上一交易日主力净流出212万元，今日环比增加408.96%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为70.00%，平均跌幅为1.35%。该股近5个交易日下跌2.82%，主力资金累计净流出492万元；近20日主力资金累计净流出5809万元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404031616178aec864b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404031616178aec864b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424683518","title":"财报对对碰丨销售费用增了研发降了，君实与信达谁能先盈亏平衡？","url":"https://stock-news.laohu8.com/highlight/detail?id=2424683518","media":"中新经纬","top":-1,"share":"https://www.laohu8.com/m/news/2424683518?lang=zh_cn&edition=full","pubTime":"2024-04-03 13:58","pubTimestamp":1712123907,"startTime":"0","endTime":"0","summary":"时逢财报披露季，多家医药企业公布2023年度业绩。同样拥有PD-1产品，且获批时间较早的生物科技公司信达生物与君实生物2023年业绩如何？PD-1单抗卖得怎么样？均实现减亏3月中下旬，信达生物与君实生物先后披露了2023年财报。信达生物在报告期内实现营业收入为62.06亿元，同比增加36.2%；君实生物实现营业收入为15.03亿元，同...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OmTH4O4rRRcEpboZdBRipKfgWw9DnSMyKxX4Ud7NNtACwAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OmTH4O4rRRcEpboZdBRipKfgWw9DnSMyKxX4Ud7NNtACwAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240403A04VO000","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240403A04VO000","is_publish_highlight":false,"gpt_icon":0},{"id":"2424044857","title":"财报对对碰丨销售费用增了研发降了，君实与信达谁能先盈亏平衡？","url":"https://stock-news.laohu8.com/highlight/detail?id=2424044857","media":"中新经纬","top":-1,"share":"https://www.laohu8.com/m/news/2424044857?lang=zh_cn&edition=full","pubTime":"2024-04-03 13:58","pubTimestamp":1712123907,"startTime":"0","endTime":"0","summary":"2023年，信达生物年内亏损约10.28亿元，较2022年末同比减少52.8%。从其财务指标来看，报告期内，信达生物销售费用增长，行政支出和研发投入下降，年内销售及市场推广开支为31.01亿元，同比增长近20%，研发投入为22.28亿元，同比下降22.41%。2023年，“V观财报”注意到，君实生物与信达生物的PD-1均实现销售额增长。君实生物财报显示，2023年特瑞普利单抗的产、销量增速分别为36.53%和23.50%，特瑞普利单抗共实现销售收入9.19亿元，同比增长25%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040314034287d92034&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040314034287d92034&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424037436","title":"【港股通】信达生物(01801)信迪利单抗与呋喹替尼的联合疗法的新药上市获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2424037436","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2424037436?lang=zh_cn&edition=full","pubTime":"2024-04-02 12:32","pubTimestamp":1712032374,"startTime":"0","endTime":"0","summary":"金吾财讯 | 信达生物(01801)公告，中国国家药品监督管理局（“NMPA”）已经正式受理信迪利单抗与呋喹替尼的联合疗法的新药上市申请（“NDA”）并授予优先审评资格，用于治疗既往系统性抗肿瘤治疗后疾病进展且不适合进行根治性手术治疗或根治性放疗的晚期错配修复完整（“pMMR”）或非微卫星高度不稳定（“非MSI-H”）的子宫内膜癌患者。FRUSICA-1研究的数据支持了此项NDA。FRUSICA-1是一项多中心、开放式标签的II期临床试验的子宫内膜癌注册队列，旨在评估信迪利单抗联合呋喹替尼治疗含铂双药化疗治疗后疾病复发、疾病进展或出现不可耐受的毒性的子宫内膜癌患者。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/ZDY0NWIyNDdlODEwMTc4NjgzODczNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDY0NWIyNDdlODEwMTc4NjgzODczNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1934331","is_publish_highlight":false,"gpt_icon":0},{"id":"2424203743","title":"信达生物(01801)：国家药监局受理信迪利单抗联合呋喹替尼用于治疗晚期子宫内膜癌的新药上市申请并授予优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2424203743","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2424203743?lang=zh_cn&edition=full","pubTime":"2024-04-02 12:30","pubTimestamp":1712032254,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，中国国家药品监督管理局已经正式受理信迪利单抗与呋喹替尼的联合疗法的新药上市申请并授予优先审评资格，用于治疗既往系统性抗肿瘤治疗后疾病进展且不适合进行根治性手术治疗或根治性放疗的晚期错配修复完整或非微卫星高度不稳定的子宫内膜癌患者。在全球范围内，2020年估计新增41.7万例子宫内膜癌新症，并造成约9.7万人死亡。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1097631.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424608290","title":"信达生物3月28日获南向资金加仓133.36万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2424608290","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424608290?lang=zh_cn&edition=full","pubTime":"2024-04-02 09:31","pubTimestamp":1712021475,"startTime":"0","endTime":"0","summary":"3月28日, 南向资金增持信达生物133.36万股。截止当日收盘，港股通共持有信达生物32783.15万股，占流通股20.20%。信达生物近5个交易日下跌1.05%，港股通累计减持313.02万股；近20个交易日下跌10.98%，港股通累计减持788.58万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404020944468ae6453c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404020944468ae6453c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424365357","title":"上海证券：全新机制口服降压药获FDA批准上市 关注心血管药物赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2424365357","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2424365357?lang=zh_cn&edition=full","pubTime":"2024-04-01 10:23","pubTimestamp":1711938227,"startTime":"0","endTime":"0","summary":"上海证券主要观点如下：全新机制口服降压药Tryvio获批2024年3月19日，美国FDA宣布批准Idorsia研发的新分子实体药物Tryvio上市。诺和诺德扩充心血管药物管线，PCSK9势头强劲近日，诺和诺德宣布，将以10.3亿欧元的价格收购Cardior Pharmaceuticals，以期进一步扩充心血管药物管线。2023年8月有两款PCSK9抑制剂新药获批上市，分别是信达生物自主研发的托莱西单抗，和诺华的英克司兰钠注射液。目前，恒瑞医药、君实生物的PCSK9单抗均已申请上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1096796.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2423214294","title":"信达生物(01801)抗CTLA-4单抗+抗PD-1单抗拟纳入突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2423214294","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2423214294?lang=zh_cn&edition=full","pubTime":"2024-03-30 09:44","pubTimestamp":1711763080,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月29日，中国国家药监局药品审评中心官网公示，信达生物IBI310及信迪利单抗两款产品拟纳入突破性治疗品种，针对适应症为IBI310联合信迪利单抗用于可切除的高微卫星不稳定性或错配修复基因缺陷型结肠癌的新辅助治疗。据悉，IBI310是信达生物自主研发的重组全人源抗CTLA-4单克隆抗体注射液。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1096655.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422907064","title":"【券商聚焦】国盛证券维持信达生物(01801)“买入”评级 料公司非肿瘤管线加速兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2422907064","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2422907064?lang=zh_cn&edition=full","pubTime":"2024-03-28 10:59","pubTimestamp":1711594765,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国盛证券发布研报指，信达生物 发布2023年业绩，公司2023年实现总收入62.06亿元，同比增长36.2%；经调整亏损额为5.15亿元，2022年同期为24.62亿元，同比减亏79.1%。该行指，目前公司已有10款产品实现商业化，3款产品提交NDA，5款产品进入3期/关键性临床，18款产品处于早期临床。非肿瘤领域布局代谢&心血管、内分泌、眼科，已有PCSK9单抗获批上市、玛仕度肽NDA获受理，IGF-1R单抗、IL23p19单抗有望2024年内申报。看好公司国际化发展，维持“买入”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1934230","is_publish_highlight":false,"gpt_icon":0},{"id":"2422604452","title":"南向资金3月26日净卖出信达生物205.87万股 连续5日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2422604452","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422604452?lang=zh_cn&edition=full","pubTime":"2024-03-27 09:31","pubTimestamp":1711503068,"startTime":"0","endTime":"0","summary":"3月26日，南向资金减持信达生物205.87万股连续5日减持。截止当日收盘，港股通共持有信达生物32678.15万股，占流通股20.13%。港股通减持金额前五个股分别为中芯国际、中国儒意、石药集团、信达生物、快手-W。信达生物近5个交易日下跌0.64%，港股通累计减持1165.73万股；近20个交易日下跌8.65%，港股通累计减持1099.99万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403270942538b678d58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403270942538b678d58&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.1111},{"period":"1month","weight":-0.1563},{"period":"3month","weight":-0.0829},{"period":"6month","weight":-0.2472},{"period":"1year","weight":-0.1541},{"period":"ytd","weight":-0.2234}],"compareEarnings":[{"period":"1week","weight":-0.0298},{"period":"1month","weight":-0.0193},{"period":"3month","weight":0.0598},{"period":"6month","weight":-0.0552},{"period":"1year","weight":-0.2046},{"period":"ytd","weight":-0.0483}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销，以及提供咨询及研发服务。该公司的主要产品为达伯舒（信迪利单抗注射液），用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303，用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305，用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌（NSCLC）。利妥昔单抗生物类似药IBI-301，用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.049204},{"month":2,"riseRate":0.666667,"avgChangeRate":0.101831},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.050735},{"month":4,"riseRate":0.5,"avgChangeRate":-0.000279},{"month":5,"riseRate":0.4,"avgChangeRate":0.023793},{"month":6,"riseRate":0.6,"avgChangeRate":0.132633},{"month":7,"riseRate":0.2,"avgChangeRate":-0.046248},{"month":8,"riseRate":0.8,"avgChangeRate":-0.016733},{"month":9,"riseRate":0.6,"avgChangeRate":0.024076},{"month":10,"riseRate":0.4,"avgChangeRate":0.043974},{"month":11,"riseRate":0.5,"avgChangeRate":0.068539},{"month":12,"riseRate":0.5,"avgChangeRate":0.07208}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}